At the time of writing, Lineage Cell Therapeutics Inc [LCTX] stock is trading at $1.30, up 15.04%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The LCTX shares have gain 17.12% over the last week, with a monthly amount glided 23.81%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 7, March 2024, Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update. In a post published today on Yahoo Finance, Advanced OpRegen® For Dry AMD in Phase 2a Study in Collaboration with Roche and Genentech.
From an analyst’s perspective:
Lineage Cell Therapeutics Inc [AMEX: LCTX] stock has seen the most recent analyst activity on November 02, 2022, when Robert W. Baird initiated its Outperform rating and assigned the stock a price target of $5. Previously, B. Riley Securities started tracking the stock with Buy rating on June 14, 2022, and set its price target to $4. On August 19, 2021, Noble Capital Markets initiated with a Outperform rating and assigned a price target of $8 on the stock. Cantor Fitzgerald started tracking the stock assigning a Overweight rating and suggested a price target of $6 on March 31, 2021.
For the past year, the stock price of Lineage Cell Therapeutics Inc fluctuated between $0.84 and $1.57. Lineage Cell Therapeutics Inc [AMEX: LCTX] shares were valued at $1.30 at the most recent close of the market.
Analyzing the LCTX fundamentals
According to Lineage Cell Therapeutics Inc [AMEX:LCTX], the company’s sales were 8.95M for trailing twelve months, which represents an 9.03% jump. Gross Profit Margin for this corporation currently stands at 0.94% with Operating Profit Margin at -2.85%, Pretax Profit Margin comes in at -2.84%, and Net Profit Margin reading is -2.66%. To continue investigating profitability, this company’s Return on Assets is posted at -0.23, Equity is -0.34 and Total Capital is -0.3. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.05.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.1533 points at the first support level, and at 1.0067 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.4333, and for the 2nd resistance point, it is at 1.5667.
Lineage Cell Therapeutics Inc [LCTX] reported earnings per share of -$0.03 for its fiscal quarter that ended on 12/30/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.04/share, meaning a difference of $0.01 and a surprise factor of 25.00%. By comparison, the stated earnings for the previous quarter ended on 9/29/2023 were -$0.04 per share as compared to estimates of -$0.04 per share, a difference of $0 representing a surprise of 0.00%.
Ratios To Look Out For
It is important to note that Lineage Cell Therapeutics Inc [AMEX:LCTX] has a current ratio of 2.14. Also, the Quick Ratio is 2.14, while the Cash Ratio stands at 1.97. Considering the valuation of this stock, the price to sales ratio is 27.38, the price to book ratio is 3.59.
Transactions by insiders
Recent insider trading involved BAILEY DON M, Director, that happened on Feb 08 ’24 when 96155.0 shares were purchased. Director, BROADWOOD PARTNERS, L.P. completed a deal on Feb 06 ’24 to buy 6.73 million shares. Meanwhile, Director Jayasuriya Anula bought 10000.0 shares on Dec 29 ’23.
